These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. Di Stilo A; Visentin S; Cena C; Gasco AM; Ermondi G; Gasco A J Med Chem; 1998 Dec; 41(27):5393-401. PubMed ID: 9876109 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents. Hosseini M; Miri R; Amini M; Mirkhani H; Hemmateenejad B; Ghodsi S; Alipour E; Shafiee A Arch Pharm (Weinheim); 2007 Oct; 340(10):549-56. PubMed ID: 17849444 [TBL] [Abstract][Full Text] [Related]
7. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method. Hemmateenejad B; Miri R; Akhond M; Shamsipur M Arch Pharm (Weinheim); 2002 Dec; 335(10):472-80. PubMed ID: 12506395 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, rotamer orientation, and calcium channel modulation activities of alkyl and 2-phenethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(3- or 6-substituted-2-pyridyl)-5-pyridinecarboxylates. Iqbal N; Akula MR; Vo D; Matowe WC; McEwen CA; Wolowyk MW; Knaus EE J Med Chem; 1998 May; 41(11):1827-37. PubMed ID: 9599233 [TBL] [Abstract][Full Text] [Related]
9. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels. Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623 [TBL] [Abstract][Full Text] [Related]
10. Pattern of interaction between dihydropyridine calcium antagonists and cationic amphiphilic drugs in isolated guinea-pig left atria. Schröder F; Herzig S Arzneimittelforschung; 1993 Nov; 43(11):1148-51. PubMed ID: 8292056 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers. Ramesh M; Matowe WC; Akula MR; Vo D; Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Knaus EE J Med Chem; 1998 Feb; 41(4):509-14. PubMed ID: 9484501 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine). Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425 [TBL] [Abstract][Full Text] [Related]
13. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities. Liang JC; Yeh JL; Wang CS; Liou SF; Tsai CH; Chen IJ Bioorg Med Chem; 2002 Mar; 10(3):719-30. PubMed ID: 11814861 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. Yamamoto T; Niwa S; Ohno S; Onishi T; Matsueda H; Koganei H; Uneyama H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M Bioorg Med Chem Lett; 2006 Feb; 16(4):798-802. PubMed ID: 16309909 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological profile of some chloroxanthone-1, 4-dihydropyridine derivatives. Bisi A; Budriesi R; Rampa A; Fabbri G; Chiarini A; Valenti P Arzneimittelforschung; 1996 Sep; 46(9):848-51. PubMed ID: 8876931 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Miri R; Javidnia K; Sarkarzadeh H; Hemmateenejad B Bioorg Med Chem; 2006 Jul; 14(14):4842-9. PubMed ID: 16603367 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-[3-(1-methoxy-carbonyl-4-substituted-1,4- dihydro-pyridyl)]-3,5-pyridinedicarboxylates. Ramesh M; Matowe WC; Knaus EE; Wolowyk MW Drug Des Discov; 1992 Jul; 8(4):313-23. PubMed ID: 1445996 [TBL] [Abstract][Full Text] [Related]
18. [Vasodilator effects of LF 2.0254, a new 1,4-dihydropyridine. Comparison with nifedipine]. Pruneau D; Roy F; Brown NL Therapie; 1989; 44(3):203-8. PubMed ID: 2781506 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and cardiodepressant activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pentatomic-heteroaryl)-3,5-pyridine-dicarbo xylates. 2. Baraldi PG; Garuti L; Leoni A; Cacciari B; Budriesi R; Chiarini A Drug Des Discov; 1993; 10(4):319-29. PubMed ID: 8148471 [TBL] [Abstract][Full Text] [Related]
20. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers. Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]